Profile
Chenicheri Hariharan Nair served as a Non-Executive Deputy Chairman at Memphasys Ltd.
from 2012 to 2013.
He was also an Executive Chairman at PrIME Biologics Pte Ltd.
Additionally, he worked as a Director at Arturus Capital Ltd.
from 2004 to 2007.
Nair holds a doctorate degree from the Australian National University.
Former positions of Chenicheri Hariharan Nair
| Companies | Position | End |
|---|---|---|
| MEMPHASYS | President | 30/11/2012 |
Arturus Capital Ltd.
 Arturus Capital Ltd. Financial ConglomeratesFinance Arturus Capital Ltd. is an investment company that holds interests in mining and gas projects. The company was founded on May 31, 1972 and is headquartered in North Perth, Australia. | Director/Board Member | 21/12/2007 |
PrIME Biologics Pte Ltd.
 PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Chairman | - |
Training of Chenicheri Hariharan Nair
| Australian National University | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEMPHASYS | Health Technology |
| Private companies | 2 |
|---|---|
Arturus Capital Ltd.
Arturus Capital Ltd. Financial ConglomeratesFinance Arturus Capital Ltd. is an investment company that holds interests in mining and gas projects. The company was founded on May 31, 1972 and is headquartered in North Perth, Australia. | Finance |
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |
- Stock Market
- Insiders
- Chenicheri Hariharan Nair
